Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20994190 | 0.85 | — | — | |
| SCHEMBL12476456 | 0.82 | OXER1 (0.32) | OXER1ALOX5PLA2G4A | |
| SCHEMBL1818263 | 0.82 | FAAH (0.50) | FAAHCES1PLA2G4AALDH1A1PLA2G4B | |
| SCHEMBL1818265 | 0.82 | FAAH (0.50) | FAAHCES1PLA2G4AALDH1A1PLA2G4B | |
| SCHEMBL12476453 | 0.82 | OXER1 (0.32) | OXER1ALOX5PLA2G4A | |
| SCHEMBL12477607 | 0.82 | OXER1 (0.38) | OXER1ALOX5ACLYPLA2G4A | |
| SCHEMBL12477608 | 0.82 | OXER1 (0.38) | OXER1ALOX5ACLYPLA2G4A | |
| SCHEMBL14931773 | 0.82 | ALDH1A1 (0.38) | OXER1ALOX5ACLYFAAHCES1 | |
| SCHEMBL1428312 | 0.82 | FAAH (0.41) | OXER1ALOX5ACLYFAAHCES1 | |
| SCHEMBL11254804 | 0.80 | FAAH (0.32) | OXER1ACLYFAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210207014-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | THE CHEMOURS COMPANY FC, LLC (US) | 2021-07-08 | — | — | US | disclosed |
| US-9540557-B2 | Compositions comprising fluoroolefins and uses thereof | THE CHEMOURS COMPANY FC, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150068227-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-12 | — | — | US | disclosed |
| US-20100132387-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100127208-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127208-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | GFPT1, PFAS, TRMT1 | OXER1 4152/4885ALOX5 761/4885ACLY 2728/4885 |
| US-20210207014-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | GFPT1, PFAS, TRMT1 | OXER1 4152/4885ALOX5 761/4885ACLY 2728/4885 |
| US-20100132387-A1 | COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF | GFPT1, PFAS, TRMT1 | OXER1 4152/4885ALOX5 761/4885ACLY 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.